Toxicity management of regorafenib in patients with gastro-intestinal stromal tumour (GIST) in a tertiary cancer centre

BACKGROUND: Regorafenib is a multi-kinase inhibitor approved as third line treatment for metastatic GIST. Dose limiting toxicities are frequently seen and many patients require dose reductions. This study aimed to evaluate regorafenib toxicities and their management in a real-world GIST population....

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Clin Sarcoma Res
Asıl Yazarlar: Chamberlain, Florence, Farag, Sheima, Williams-Sharkey, Constance, Collingwood, Cecilia, Chen, Lucia, Mansukhani, Sonia, Engelmann, Bodil, Al-Muderis, Omar, Chauhan, Dharmisha, Thway, Khin, Fisher, Cyril, Jones, Robin L., Gennatas, Spyridon, Benson, Charlotte
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2020
Konular:
Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6942401/
https://ncbi.nlm.nih.gov/pubmed/31911828
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13569-019-0123-4
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller